Drug Trial Radar · NCT07886684
A Clinical Trial to Test if the Investigational Drug BNT3210 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker Sialyl-Tn
Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
173
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Oct 2029
Study completion Apr 2030
Sponsor
- Lead sponsor
- BioNTech SEIndustry
- Sponsor type
- Industry
- Collaborators
- BioNTech (Shanghai) Pharmaceuticals Co., Ltd.
- First posted
- Oct 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is the first time BNT3210 will be tested in people. It will evaluate different dose levels to find suitable doses and to understand how safe the treatment is and how it may help people with advanced solid tumors.
Conditions
- Advanced Solid Tumors
Interventions
BNT3210Drug
Intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A only: Occurrence of dose-limiting toxicities (DLTs) during the DLT evaluation periodTime frame: Up to 21 days from the initiation of first dose of study treatment
- Occurrence of treatment emergent adverse events (TEAEs) by grade, seriousness, and relatednessTime frame: Up to approximately 3 years from first dose of study treatment
- Occurrence of dose interruptions, reductions, and discontinuation of BNT3210 due to TEAEsTime frame: Up to approximately 3 years from first dose of study treatment
- Part B only: Objective response rate (ORR)Time frame: Up to approximately 3 years from first dose of study treatment
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.